검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Albumin-paclitaxel + platinum (Albumin-paclitaxel + platinum) AstraZeneca·Salivary Gland Carcinoma ORR 64.3% |
|---|---|
Overview Program | Albumin-paclitaxel + platinum |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Salivary Gland Carcinoma |
Overview Indication | Salivary Gland Carcinoma; Precision Therapy |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.. To compare the clinical efficacy and adverse reactions associated with nano-albumin paclitaxel combined with cisplatin and traditional paclitaxel combined with cisplatin for the treatment of non-small cell lung cancer. From December 2016 to August 2019, 78 patients with non-small cell lung cancer in … |
Clinical Primary efficacy | ORR 64.3% |
Clinical ORR | 64.3% |
Clinical Result source | ClinicalTrials.gov NCT06212752 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Albumin-paclitaxel + platinum (Albumin-paclitaxel + platinum) AstraZeneca·Salivary Gland Carcinoma ORR 64.3% |
|---|---|
Overview Program | Albumin-paclitaxel + platinum |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Salivary Gland Carcinoma |
Overview Indication | Salivary Gland Carcinoma; Precision Therapy |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.. To compare the clinical efficacy and adverse reactions associated with nano-albumin paclitaxel combined with cisplatin and traditional paclitaxel combined with cisplatin for the treatment of non-small cell lung cancer. From December 2016 to August 2019, 78 patients with non-small cell lung cancer in … |
Clinical Primary efficacy | ORR 64.3% |
Clinical ORR | 64.3% |
Clinical Result source | ClinicalTrials.gov NCT06212752 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교